Pathogenic mutations in APP, PSEN1, PSEN2, MAPT and GRN have previously been linked to familial early onset forms of dementia. Mutation screening in these genes has been performed in either very small series or in single families with late onset AD (LOAD). Similarly, studies in single families have reported mutations in MAPT and GRN associated with clinical AD but no systematic screen of a large dataset has been performed to determine how frequently this occurs. We report sequence data for 439 probands from late-onset AD families with a history of four or more affected individuals. Sixty sequenced individuals (13.7%) carried a novel or pathogenic mutation. Eight pathogenic variants, (one each in APP and MAPT, two in PSEN1 and four in GRN) three of which are novel, were found in 14 samples. Thirteen additional variants, present in 23 families, did not segregate with disease, but the frequency of these variants is higher in AD cases than controls, indicating that these variants may also modify risk for disease. The frequency of rare variants in these genes in this series is significantly higher than in the 1,000 genome project (p = 5.09×10？5; OR = 2.21; 95%CI = 1.49–3.28) or an unselected population of 12,481 samples (p = 6.82×10？5; OR = 2.19; 95%CI = 1.347–3.26). Rare coding variants in APP, PSEN1 and PSEN2, increase risk for or cause late onset AD. The presence of variants in these genes in LOAD and early-onset AD demonstrates that factors other than the mutation can impact the age at onset and penetrance of at least some variants associated with AD. MAPT and GRN mutations can be found in clinical series of AD most likely due to misdiagnosis. This study clearly demonstrates that rare variants in these genes could explain an important proportion of genetic heritability of AD, which is not detected by GWAS.
References
[1]
Cruts M, van Duijn CM, Backhovens H, Van den Broeck M, Wehnert A, et al. (1998) Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. Hum Mol Genet 7: 43–51.
[2]
Rogaeva EA, Fafel KC, Song YQ, Medeiros H, Sato C, et al. (2001) Screening for PS1 mutations in a referral-based series of AD cases: 21 novel mutations. Neurology 57: 621–625.
[3]
Brickell KL, Leverenz JB, Steinbart EJ, Rumbaugh M, Schellenberg GD, et al. (2007) Clinicopathological concordance and discordance in three monozygotic twin pairs with familial Alzheimer's disease. J Neurol Neurosurg Psychiatry 78: 1050–1055.
[4]
Athan ES, Williamson J, Ciappa A, Santana V, Romas SN, et al. (2001) A founder mutation in presenilin 1 causing early-onset Alzheimer disease in unrelated Caribbean Hispanic families. Jama 286: 2257–2263.
[5]
Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, et al. (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349: 704–706.
[6]
Kauwe JS, Jacquart S, Chakraverty S, Wang J, Mayo K, et al. (2007) Extreme cerebrospinal fluid amyloid beta levels identify family with late-onset Alzheimer's disease presenilin 1 mutation. Ann Neurol 61: 446–453.
[7]
Devi G, Fotiou A, Jyrinji D, Tycko B, DeArmand S, et al. (2000) Novel presenilin 1 mutations associated with early onset of dementia in a family with both early-onset and late-onset Alzheimer disease. Archives of Neurology 57: 1454–1457.
[8]
Larner AJ, Ray PS, Doran M (2007) The R269H mutation in presenilin-1 presenting as late-onset autosomal dominant Alzheimer's disease. J Neurol Sci 252: 173–176.
[9]
Jayadev S, Leverenz JB, Steinbart E, Stahl J, Klunk W, et al. (2010) Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2. Brain: a journal of neurology 133: 1143–1154.
[10]
Tomaino C, Bernardi L, Anfossi M, Costanzo A, Ferrise F, et al. (2007) Presenilin 2 Ser130Leu mutation in a case of late-onset “sporadic” Alzheimer's disease. Journal of Neurology 254: 391–393.
[11]
Arango D, Cruts M, Torres O, Backhovens H, Serrano ML, et al. (2001) Systematic genetic study of Alzheimer disease in Latin America: mutation frequencies of the amyloid beta precursor protein and presenilin genes in Colombia. American journal of medical genetics 103: 138–143.
[12]
Scacchi R, Gambina G, Moretto G, Corbo RM (2007) A mutation screening by DHPLC of PSEN1 and APP genes reveals no significant variation associated with the sporadic late-onset form of Alzheimer's disease. Neuroscience letters 418: 282–285.
[13]
Taddei K, Fisher C, Laws SM, Martins G, Paton A, et al. (2002) Association between presenilin-1 Glu318Gly mutation and familial Alzheimer's disease in the Australian population. Molecular Psychiatry 7: 776–781.
[14]
de Silva R, Weiler M, Morris HR, Martin ER, Wood NW, et al. (2001) Strong association of a novel Tau promoter haplotype in progressive supranuclear palsy. Neurosci Lett 311: 145–148.
[15]
Houlden H, Crawford F, Rossor M, Mullan M (1993) Screening for the APP codon 670/671 mutations in Alzheimer's disease. Neuroscience letters 154: 161–162.
[16]
Tanzi RE, Vaula G, Romano DM, Mortilla M, Huang TL, et al. (1992) Assessment of amyloid beta-protein precursor gene mutations in a large set of familial and sporadic Alzheimer disease cases. American journal of human genetics 51: 273–282.
[17]
Kamino K, Orr HT, Payami H, Wijsman EM, Alonso ME, et al. (1992) Linkage and mutational analysis of familial Alzheimer disease kindreds for the APP gene region. American journal of human genetics 51: 998–1014.
[18]
Van Deerlin VM, Wood EM, Moore P, Yuan W, Forman MS, et al. (2007) Clinical, genetic, and pathologic characteristics of patients with frontotemporal dementia and progranulin mutations. Arch Neurol 64: 1148–1153.
[19]
Huey ED, Grafman J, Wassermann EM, Pietrini P, Tierney MC, et al. (2006) Characteristics of frontotemporal dementia patients with a Progranulin mutation. Ann Neurol 60: 374–380.
[20]
Cortini F, Fenoglio C, Guidi I, Venturelli E, Pomati S, et al. (2008) Novel exon 1 progranulin gene variant in Alzheimer's disease. Eur J Neurol 15: 1111–1117.
[21]
Kelley BJ, Haidar W, Boeve BF, Baker M, Shiung M, et al. (2010) Alzheimer disease-like phenotype associated with the c.154delA mutation in progranulin. Arch Neurol 67: 171–177.
[22]
Rademakers R, Baker M, Gass J, Adamson J, Huey ED, et al. (2007) Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C？>T (Arg493X) mutation: an international initiative. Lancet Neurol 6: 857–868.
[23]
Brouwers N, Nuytemans K, van der Zee J, Gijselinck I, Engelborghs S, et al. (2007) Alzheimer and Parkinson diagnoses in progranulin null mutation carriers in an extended founder family. Arch Neurol 64: 1436–1446.
[24]
Lindquist SG, Holm IE, Schwartz M, Law I, Stokholm J, et al. (2008) Alzheimer disease-like clinical phenotype in a family with FTDP-17 caused by a MAPT R406W mutation. European journal of neurology: the official journal of the European Federation of Neurological Societies 15: 377–385.
[25]
Rademakers R, Dermaut B, Peeters K, Cruts M, Heutink P, et al. (2003) Tau (MAPT) mutation Arg406Trp presenting clinically with Alzheimer disease does not share a common founder in Western Europe. Human mutation 22: 409–411.
[26]
Momeni P, Pittman A, Lashley T, Vandrovcova J, Malzer E, et al. (2009) Clinical and pathological features of an Alzheimer's disease patient with the MAPT Delta K280 mutation. Neurobiology of aging 30: 388–393.
[27]
Ludolph AC, Kassubek J, Landwehrmeyer BG, Mandelkow E, Mandelkow EM, et al. (2009) Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol 16: 297–309.
[28]
Reed LA, Grabowski TJ, Schmidt ML, Morris JC, Goate A, et al. (1997) Autosomal dominant dementia with widespread neurofibrillary tangles. Ann Neurol 42: 564–572.
[29]
The AlzGene DatabaseAlzheimer Research Forum. Available at: http://www.alzgene.org. (Accessed 09/27/2011).
[30]
Gatz M, Reynolds CA, Fratiglioni L, Johansson B, Mortimer JA, et al. (2006) Role of genes and environments for explaining Alzheimer disease. Archives of general psychiatry 63: 168–174.
[31]
Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, et al. (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41: 1088–1093.
[32]
Lambert JC, Heath S, Even G, Campion D, Sleegers K, et al. (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41: 1094–1099.
[33]
Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, et al. (2010) Genome-wide analysis of genetic loci associated with Alzheimer disease. Jama 303: 1832–1840.
[34]
Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, et al. (2011) Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics 43: 429–435.
[35]
Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, et al. (2011) Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nature Genetics 43: 436–441.
[36]
Ertekin-Taner N (2010) Genetics of Alzheimer disease in the pre- and post-GWAS era. Alzheimers Res Ther 2: 3.
[37]
So HC, Gui AH, Cherny SS, Sham PC (2011) Evaluating the heritability explained by known susceptibility variants: a survey of ten complex diseases. Genetic epidemiology 35: 310–317.
[38]
Nejentsev S, Walker N, Riches D, Egholm M, Todd JA (2009) Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. Science 324: 387–389.
[39]
Azzopardi D, Dallosso AR, Eliason K, Hendrickson BC, Jones N, et al. (2008) Multiple rare nonsynonymous variants in the adenomatous polyposis coli gene predispose to colorectal adenomas. Cancer Res 68: 358–363.
[40]
Masson E, Chen JM, Scotet V, Le Marechal C, Ferec C (2008) Association of rare chymotrypsinogen C (CTRC) gene variations in patients with idiopathic chronic pancreatitis. Hum Genet 123: 83–91.
[41]
Ma X, Liu Y, Gowen BB, Graviss EA, Clark AG, et al. (2007) Full-exon resequencing reveals toll-like receptor variants contribute to human susceptibility to tuberculosis disease. PLoS One 2: e1318.
[42]
Kamboh MI, Aston CE, Perez-Tur J, Kokmen E, Ferrell RE, et al. (1999) A novel mutation in the apolipoprotein E gene (APOE*4 Pittsburgh) is associated with the risk of late-onset Alzheimer's disease. Neurosci Lett 263: 129–132.
[43]
Kim M, Suh J, Romano D, Truong MH, Mullin K, et al. (2009) Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate {alpha}-secretase activity. Hum Mol Genet 18: 3987–3996.
[44]
Druley TE, Vallania FL, Wegner DJ, Varley KE, Knowles OL, et al. (2009) Quantification of rare allelic variants from pooled genomic DNA. Nat Methods 6: 263–265.
[45]
Vallania FL, Druley TE, Ramos E, Wang J, Borecki I, et al. (2010) High-throughput discovery of rare insertions and deletions in large cohorts. Genome Res 20: 1711–1718.
[46]
Exome Variant Server. Available: http://evsgswashingtonedu/EVS/). Accessed 2011 Nov 1.
[47]
Yu CE, Bird TD, Bekris LM, Montine TJ, Leverenz JB, et al. (2010) The spectrum of mutations in progranulin: a collaborative study screening 545 cases of neurodegeneration. Arch Neurol 67: 161–170.
[48]
Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, et al. (2010) A method and server for predicting damaging missense mutations. Nat Methods 7: 248–249.
[49]
Genin E, Hannequin D, Wallon D, Sleegers K, Hiltunen M, et al. (2011) APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Molecular Psychiatry.
[50]
Gerrish A, Russo G, Richards A, Moskvina V, Ivanov D, et al. (2011) The Role of Variation at AbetaPP, PSEN1, PSEN2, and MAPT in Late Onset Alzheimer's Disease. J Alzheimers Dis.
[51]
Gass J, Cannon A, Mackenzie IR, Boeve B, Baker M, et al. (2006) Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet 15: 2988–3001.
[52]
Pickering-Brown SM, Baker M, Gass J, Boeve BF, Loy CT, et al. (2006) Mutations in progranulin explain atypical phenotypes with variants in MAPT. Brain 129: 3124–3126.
[53]
Mesulam M, Johnson N, Krefft TA, Gass JM, Cannon AD, et al. (2007) Progranulin mutations in primary progressive aphasia: the PPA1 and PPA3 families. Arch Neurol 64: 43–47.
[54]
Spina S, Murrell JR, Huey ED, Wassermann EM, Pietrini P, et al. (2007) Clinicopathologic features of frontotemporal dementia with Progranulin sequence variation. Neurology.
[55]
Rossor MN, Fox NC, Beck J, Campbell TC, Collinge J (1996) Incomplete penetrance of familial Alzheimer's disease in a pedigree with a novel presenilin-1 gene mutation. Lancet 347: 1560.
[56]
Llado A, Fortea J, Ojea T, Bosch B, Sanz P, et al. (2010) A novel PSEN1 mutation (K239N) associated with Alzheimer's disease with wide range age of onset and slow progression. Eur J Neurol 17: 994–996.
[57]
Le Ber I, van der Zee J, Hannequin D, Gijselinck I, Campion D, et al. (2007) Progranulin null mutations in both sporadic and familial frontotemporal dementia. Hum Mutat 28: 846–855.
[58]
Foster NL, Heidebrink JL, Clark CM, Jagust WJ, Arnold SE, et al. (2007) FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain 130: 2616–2635.
[59]
Silverman JM, Smith CJ, Marin DB, Mohs RC, Propper CB (2003) Familial patterns of risk in very late-onset Alzheimer disease. Arch Gen Psychiatry 60: 190–197.
[60]
Silverman JM, Ciresi G, Smith CJ, Marin DB, Schnaider-Beeri M (2005) Variability of familial risk of Alzheimer disease across the late life span. Arch Gen Psychiatry 62: 565–573.
[61]
Mendez MF, McMurtray A (2006) Frontotemporal dementia-like phenotypes associated with presenilin-1 mutations. Am J Alzheimers Dis Other Demen 21: 281–286.
[62]
Bernardi L, Tomaino C, Anfossi M, Gallo M, Geracitano S, et al. (2009) Novel PSEN1 and PGRN mutations in early-onset familial frontotemporal dementia. Neurobiol Aging 30: 1825–1833.
[63]
Marcon G, Di Fede G, Giaccone G, Rossi G, Giovagnoli AR, et al. (2009) A novel Italian presenilin 2 gene mutation with prevalent behavioral phenotype. J Alzheimers Dis 16: 509–511.
[64]
Wijsman EM, Pankratz ND, Choi Y, Rothstein JH, Faber KM, et al. (2011) Genome-wide association of familial late-onset Alzheimer's disease replicates BIN1 and CLU and nominates CUGBP2 in interaction with APOE. PLoS genetics 7: e1001308.
[65]
McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939–944.
[66]
Brunak S, Engelbrecht J, Knudsen S (1991) Prediction of human mRNA donor and acceptor sites from the DNA sequence. J Mol Biol 220: 49–65.
